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ABSTRACT 
Epithelial ovarian cancer (EOC) is the sixth most common malignancy in women. Ovarian tumors consist of several 
clinical and pathological entities that share an anatomic site. The gold standard treatment, both in front-line and in ad- 
juvant setting, is represented by carboplatin/paclitaxel combination. Conversely, the second-line treatment is not well 
defined. The response to platinum is the major prognostic factor for survival. In this review we discuss the current 
views on platinum-refractory/resistant patient treatment only, which includes patients progressing or relapsing within 6 
months from the last platinum-based course. Concerning this subgroup, the activity of several conventional drugs was 
confirmed in different trials without a significant impact in terms of overall survival. In the last years particular empha- 
sis was given to targeted anti-angiogenetic therapy which produced a survival improvement with an acceptable toxicity 
profile. New “ad hoc” approaches, with a major attention to outcome-predictive factors, are eagerly awaited. 
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1. Introduction 
Epithelial ovarian cancer (EOC) is the sixth most com- 
mon malignancy in women [1]. The overall 5-years sur- 
vival rate, despite of stage, is about 30% [2]. Serous pap- 
illary EOC is the most frequent type and the leading 
cause of death among gynaecological cancers. EOCs 
consist of several pathological entities that share ana- 
tomic site and frontline treatment [3]. Indeed, mutations 
that arise in EOC, such as KRAS, PIK3CA, TP53, 
BRCA1 and BRCA2, are unequally distributed between 
different subtypes [4]. Kurman et al. described that only 
serous papillary EOC seems to originate by ovary and/or 
fallopian tube, and in the contest of this histotype two 
different groups are recognized: Type I tumors arise by 
precursor lesion, are usually low grade with specific mu- 
tations in K-RAS, B-RAF, PTEN and b-catenin, present 
a normal karyotype and wild-type TP53. These mutations 
are frequently reported very early and typically these tu- 
mors are characterized by a worse response to plati- 
num-based chemotherapy. The course of these lesions is 
indolent and has been postulated to be the result of  
“multi-hit oncogenesis”. Conversely Type II is charac- 
terized by de novo lesions, high grade, genetic instability, 
TP53 mutations, RAS pathway wild-type, and BRCA 
mutations, both hereditary and sporadic (such as pro- 
moter methylation and failure in the DNA homologous 
recombination); last subgroup showed a strongly correla- 
tion with response to platinum, probably due to early loss 
of BRCA and TP53 function (Table 1) [5-13].  
In 1991, a meta-analysis on 8000 patients showed that 
platinum-based combination regimens were more ef- 
fective compared to platinum monotherapy [14]. Cur- 
rently, the gold standard treatment in frontline and in 
adjuvant setting is carboplatin/paclitaxel [15-17]. Con- 
versely, the treatment for recurrent or progressive EOC is 
not well defined. The response to platinum-containing 
first line chemotherapy is the major prognostic factor. 
Platinum-refractory status is generally considered for 
patients who relapse within 6 months from the last plati- 
num-based course [7]. Concerning this subgroup, in the 
last years, a modest activity of several drugs such as pe- 
gylated liposomial doxorubicin (PLD), topotecan, eto-  
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Table 1. Characteristics of Type I and Type II tumor. 
 Type I Type II 
Clinical features indolent aggressive 
Histological features low-grade serous high-grade serous
 low-grade endometrioid 
high-grade  
endometrioid 
 clear cell undifferentiated 
 mucinous Carcinosarcoma 
Molecular features K-RAS TP53CCNE1 
 B-RAF  
 ERBB2  
 PTEN  
 CTNNB1  
 PIK3CA  
 
poside, taxanes, gemcitabine, oxaliplatin was confirmed 
in several trials without a significant impact in terms of 
overall survival (OS). Therefore, there is not a standard 
approach for second-line treatment [18,19]. 
2. Cytotoxic Chemotherapy 
The platinum-refractory/resistant diseases represent an 
heterogeneous spectrum of tumors characterized by low 
response rate (RR) to previous carboplatin-based-sche- 
dule (10% - 25%) [18,20,21]. Conventional decision in 
this setting is exclusion of platinum in subsequent line- 
treatment [19]. Indeed, common recommendation can be 
made for the use of monotherapy with PLD, topotecan, 
etoposide, gemcitabine or paclitaxel, all producing a low 
RR without any demonstrated improvement on survival 
endpoints [18,21].  
In 2004 results by Gordon et al. described a marginal 
progression free survival (PFS) benefit for PLD com- 
pared to topotecan (especially in platinum-sensitive sub- 
group) that, in view of the good tolerability of the drug, 
was translated in platinum-refractory setting. PLD be- 
came a “first” choice for second-line treatment in all 
subgroups [22]. Subsequently, several trials did not dem- 
onstrate statistically significant results in terms of sur- 
vival gain for PLD compared to gemcitabine, that re- 
mains therefore a valid option in this setting with RR of 
20% [23-31]. By the way gemcitabine was the most com- 
mon drug used in clinical trials [32,33].  
In recent studies pemetrexed, a multitarget antifolate 
agent, produced RR similar to historical agents without 
any evident impact in term of survival [34-36]. Rose et al. 
investigated prolonged oral etoposide in both platinum- 
sensitive and platinum-resistant patients with an overall 
RR of 34% and 27% respectively [37]. 
Paclitaxel, as single agent, represents to date, a good  
clinical option in term of RR and survival, in particular if 
we consider weekly schedule [38,39]. Furthermore, the 
albumin-bound formulation of paclitaxel, nab-paclitaxel 
too, has been investigated in this setting showing similar 
RR (23%) and a median PFS of 4.7 months with a good 
tolerability [40].  
A larger study with docetaxel in monotherapy was 
conducted by Rose et al. in platinum and paclitaxel-ref- 
ractory settings with a RR of 22% [41]. The potential 
role of docetaxel-based combination regimens has not 
been rigorously evaluated. A prospective phase II study 
was conducted to evaluate the efficacy and toxicity of a 
combination of docetaxel/irinotecan as salvage treatment 
in platinum-refractory EOC patients [42]. This non-com- 
parative trial, demonstrated a marginal benefit in RR 
similar to single agent schedule, confirming that single 
agent chemotherapy should be considered the standard 
treatment for these patients. Indeed, six trials failed to 
demonstrate an advantage for combination treatment 
compared to single agent with an increased toxicity [43- 
51]. 
However, different small trials evaluating gemcitabine 
and oxaliplatin combination in this setting demonstrated 
a longer PFS and a better RR. Considering the worse 
prognosis of these patients, comparative studies of this 
doublet versus single agent are required [52,53].  
In third-line treatment a randomized phase III trial 
comparing PLD to patupilone, a novel microtubule in- 
hibitor, demonstrated a PFS advantage for PLD arm [54]. 
Similarly canfosfamide, compared to topotecan and PLD 
in second- and third-line treatment, have been found sig- 
nificantly less active than these drugs [55-58]. 
In the light of the dismissal activity of conventional 
chemotherapy, in the last years particular emphasis was 
given to targeted therapy which produced survival im- 
provement with an acceptable toxicity [59-63]. 
3. Targeted Therapy in EOC 
3.1. The Involvement of HER-Pathway in  
Platinum-Resistance 
The epidermal growth factor receptor (EGFR)-family 
play an important role in different malignancies and a 
EGFR overexpression seems to be correlated with de- 
creased survival [64]. About 30% - 98% of EOC present 
overexpression in one of these pathways. Human epi- 
dermal receptor (HER) family consist of 4 paralogs  
(HER1/EGFR, HER2/neu, HER3 and HER4) and is 
characterized by an extracellular ligand binding domain, 
a transmembrane lipophilic glycoprotein and an intracel- 
lular tyrosine kinase (TK) domain. Signaling cascade be- 
gins with bindings of growth factors, such as epidermal  
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growth factor (EGF), transforming growth factor alfa 
(TGF-α) to the receptor and subsequent dimerization or 
oligomerization and has been implicated in cancer de- 
velopment and resistance to cisplatin [65]. EGFR deter- 
mines both omo-dimerization and ethero-dimerization 
with HER2/neu. The receptor triggers the autophospho- 
rylation on tyrosine residues with signal transduction 
cascade activation. Dysregulation in EGFR promotes cell 
proliferation, migration and invasion with uncontrolled 
cellular growth and enhanced neo-angiogenesis [66]. 
Dimerization activates different signaling pathways, in 
particular EGFR dimerization activates the RAS-RAF-m- 
itogen-activated protein kinase pathway (RAS/RAF/ 
MAPK pathway) which induces oncogenesis and tumor 
progression mainly through constitutive activation of 
STAT-3 and STAT-5 and the phosphatidylinositol 3-ki- 
nase pathway (PI3K). Activation of PI3K results in the 
activation of the PDK1, AKT/PKB pathway [67].  
Cetuximab is a chimeric monoclonal antibody able to 
inhibit the binding of EGF and the autophosphorylation 
of the receptor with its internalization from the cell sur- 
face that prevents further interaction with ligand [68]. A 
small phase II trial designed on platinum-refractory/re- 
sistant EGFR positive setting on cetuximab as single 
agent demonstrated marginal benefit in term of PFS [69]. 
Matuzumab, a humanized anti-EGFR monoclonal anti- 
body, in patients heavily pretreated, did not show activity 
in this setting [70]. 
Erlotinib, a reversible EGFR-specific tyrosine kinase 
inhibitor (TKI), was evaluated as single-agent in two 
phase II trials that enrolled patients with platinum-resis- 
tant status obtaining a marginal activity limited for pa- 
tients with EGFR-positive EOC. These trials reported a 
median OS of 8 months and disease control rate (DCR) 
in 50% of patients with acceptable tolerability [71]. 
Gefitinib was evaluated in phase II trial in patients 
with platinum-resistant setting and EGFR positive, with 
median PFS 2.2 months and RR 9% [72]. Another trial in 
this setting, evaluated the combination gefitinib/tamo- 
xifen with a median time-to-progression of 58 days and 
median survival of 253 days [73]. Furthermore gefitinib 
was evaluated in combination with carboplatin and pa- 
clitaxel in patients stratified for platinum-sensitivity and 
EGFR positive and suggested advantages for platinum- 
sensitive setting only [74]. 
Trastuzumab, a monoclonal antibody targeting the 
HER2/neu, was investigated in a phase II trial on the 
basis of HER2/neu expression. This trial showed that 
activity of trastuzumab in this setting is limited by the 
low frequency of HER2 overexpression and low rate of 
objective response among patients with HER2 overex- 
pression [75]. CI-1033 (canertinib), another panERB 
inhibitor also failed to demonstrate activity in platinum-  
refractory/resistant patients [76]. Lapatinib a 4-anilino- 
quinazoline, is an inhibitor of the intracellular TK do- 
mains of both EGFR and HER2. It was investigated in 
phase II trials both as single agent and in combination 
with topotecan but was not effective. Interestingly, in this 
trial, a subset analysis about prognostic factors suggested 
that Ki-67 expression may be associated with better prior 
platinum free interval (PFI) and PFS [77,78]. 
Pertuzumab is a recombinant, humanized monoclonal 
antibody directed against human HER2 that inhibits 
ligand-activated heterodimerization with other HERs, 
most notably HER3 [79]. A phase II trial evaluated per- 
tuzumab in combination with gemcitabine in platinum- 
resistant EOC treatment demonstrated a significant ad- 
vantage in term of RR and PFS for experimental arm 
compared to gemcitabine/placebo. Furthermore, it was 
suggested that patients with low HER3 mRNA expres- 
sion, had an increase treatment benefit with pertuzumab 
[80]. 
3.2. Potential Role of mTOR Inhibitors and  
Platinum-Refractory/Resistant Ovarian  
Cancer  
mTOR is a serine and threonine protein kinase. The 
mTOR pathway is involved in cell proliferation, motility 
and survival, protein synthesis and transcription. Pre- 
clinical findings indicated that this pathway has a crucial 
role in survival and drug-resistance of cancer cells. A 
small phase II trial evaluated efficacy and toxicity profile 
of mTOR inhibitor, temsirolimus, in platinum-resistant 
EOC disease and showed a modest activity. Cyclin D1 
and circulating tumors cells (CTCs) measures where sug- 
gested as markers of outcome [81]. 
3.3. PARP Inhibitors 
About 50% of EOC display defects in the homologous 
recombination (HR) pathway. This condition, like he- 
reditary mutation in BRCA1-2, correlated to a good re- 
sponse to platinum-chemotherapy. However, Kaye et al., 
evaluated use of olaparib, a PARP inhibitor, compared to 
PLD in patients who relapsed within 12 months did not 
reach pre-specified endpoints, failing to demonstrate any 
advantage for olaparib [82].  
3.4. The Strict Interplay between Inflammation,  
Immune-System and Angiogenesis 
The role of inflammation, immune system and angiog- 
enesis in the onset and development of EOC has been 
extensively investigated during the past years [83,84]. 
The synthesis of cytokines such as TNF-α, IL-1β, IL-6, 
PGE-2 and vascular endothelial growth factor (VEGF)  
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by cells from the microenvironment (especially activated 
immune cells and stromal cells), as well as the increased 
expression of STAT-3, NF-kB, iNOS and COX-2 in tu- 
mor and tumor-surrounding cells, has been linked to poor 
prognosis, disease stage progression, residual disease 
status and the presence of ascites [83,85,86]. Among 
these molecules, IL-6 seems to play a key role in deter- 
mining platinum-resistance. Wang et al. recently re- 
ported that IL-6 production by different EOC cell lines is 
directly associated to treatment resistance. Furthermore, 
IL-6 induced cisplatin and paclitaxel-resistance when 
administered to IL-6-non-producing cell lines [87]. The 
ERK signaling pathway seems the principal mediator of 
this effect. Furthermore, IL-6 is able to induce HIF-1 via 
STAT-3, and HIF-1, in turn, promotes VEGF expression 
[88-90]. VEGF is able to enhance the malignant potential 
of EOC cells through the induction of ascites, by in- 
creasing peritoneal permeability and immune suppres- 
sion, by impairing dendritic cells maturation and Th1 
response and increasing tumor-infiltration by T regula- 
tory cells [91-93]. Moreover, Bamias et al. described an 
association between VEGF levels in ascites and plati- 
num-resistance and an inverse correlation of VEGF with 
CD3+ CD56+ Natural Killer (NK) cells [94]. On these 
basis it emerges the central role of inflammation in 
platinum-refractory EOC: the inflammatory microenvi- 
ronment induces the production and release of IL-6 and 
VEGF which in turn lead to neo-angiogenesis, ascites 
formation and immune suppression on both adaptive 
(DCs and Th1) and NK immunity.  
Tumor infiltration by different inflammatory cells has 
been correlated with prognosis and tumor progression in 
different tumors including EOC [95-98]. Among these 
cells, tumor associated macrophages (TAMs) have re- 
cently demonstrated to exert a significant immune sup- 
pressive effect together with a pro-angiogenic activity 
(M2 polarization) [99]. M2-TAMs are characterized by 
the expression of the angiopoietin receptor TIE-2 and are 
thought to be implied in VEGF-independent neo-angio- 
genesis [100]. These aspects are extremely relevant in a 
translational view, offering a solid rationale for the use of 
anti-angiogenic agents in platinum-resistant EOC. 
3.5. Anti-Angiogenetic Agents in  
Platinum-Resistant Ovarian Cancer 
Bevacizumab, antibody targeting VEGF-A, demonstrated 
clinical activity in recurrent EOC [101,102]. A small trial 
reported for heavily pre-treated patients with platinum- 
resistant treated with bevacizumab as single agent a me- 
dian PFS of 4.4 months and a median OS of 10.7 months 
[59].  
Preclinical studies showed an improvement of anti-  
tumor activity when anti-VEGF or anti-VEGFR targeting 
agents were associated to cytotoxic agent, probably due 
to vascular normalization [103,104]. A phase II trial de- 
scribed that the association of bevacizumab and metro- 
nomic oral cyclophosphamide produced a median OS of 
16.9 months [105]. Another phase II trial, that investi- 
gated a combination of bevacizumab and nab-paclitaxel 
reported a median PFS of 8.3 months and a median OS 
of 16.5 months [106]. 
Recently results of AURELIA trial, designed for this 
setting, reported that association of bevacizumab to con- 
ventional agents (PLD, topotecan or paclitaxel) was able 
to prolong PFS. In particular the arm containing weekly- 
paclitaxel/bevacizumab determined a 10.4 months PFS 
[60].  
Aflibercept, is a recombinant fusion protein between 
the constant region (Fc) of an IgG1, the second domain 
of VEGFR-1 and the third domain of VEGFR-2 that 
binds and neutralizes VEGF A, B and placental growth 
factor (PIGF) [107]. This agent seems particularly active 
in recurrent EOC patients with malignant ascites [108, 
109]. 
Imatinib and dasatinib, selective inhibitors of PDGFR 
and C-KIT, were evaluated in small phases II trials in 
recurrent EOC without any improvement both in RR and 
in survival endpoints [110,111]. 
Sorafenib, a multitarget inhibitor of B-RAF, VEGFR-2 
and -3, PDGFR-b, FLT-3, and C-KIT, was evaluated in 
phase II trials in second and third line treatment, demon- 
strating a modest activity and substantial toxicity [112, 
113]. Sunitinib, another multi-target TKI for VEGFR, 
PDGFR-A, PDGFR-B, C-KIT, FLT-3 and cediranib, a 
potent inhibitor of VEGFR, PDGFR-B and C-KIT, were 
evaluated as single agents and in combination schedules, 
in recurrent EOC patients with modest activity in terms 
of RR and and mostly restricted to the platinum-sensitive 
setting [114-117].  
Pazopanib a TKI targeting VEGFR, PDGFR, and 
C-KIT, and BIBF-1120, a VEGFR, PDGFR, and FGFR 
multi-targeted TKI were recently evaluated in combina- 
tion-schedules and as single agents in EOC patients. Data 
available, to date, showed activity of these agents and 
major trials are still ongoing [61,62,118].  
Recently a phase II trial evaluated AMG-386, an inve- 
stigational peptide-Fc fusion protein that neutralizes the 
interaction between the TIE-2 receptor and angiopoi- 
etin-1/2, in combination with weekly paclitaxel demon- 
strated the potential efficacy of this agent, with a good 
toxicity profile, warranting further studies [119]. 
Many authors proposed proangiogenic protein concen- 
tration in plasma or urine (e.g., VEGF, PDGF, PIGF) as 
markers that would predict response to anti-angiogenic  
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tatize [125]. In different studies in vitro and in vivo, in 
different tumors, miR-34 replacement/overexpression in- 
duced apoptosis and reduced cellular migration, prolife- 
ration and tumor growth [125,126].  
therapy. Several ongoing trials could confirm this hy- 
pothesis. 
3.6. MicroRNAs, New Potential Targets in  
Platinum-Refractory/Resistant EOC The miR-200 family represents another widely studied 
group of miRNA in EOC. They appeared to be implied in 
epithelial to mesenchimal transition and in resistance to 
both paclitaxel and platinum [120]. However, contrasting 
data on activity and expression of these miRNAs in EOC 
are available in literature and its role is far to be com- 
pletely understood.  
MicroRNAs (miRNAs), are short non-coding RNA 
molecules of about 19 - 25 nucleotides able to regulate 
gene expression at post-trascriptional level by binding 
specific target mRNAs [120,121]. Several recently pub- 
lished studies focus their attention on the role played by 
these molecules in EOC initiation and progression. 
miR-21 is one of the most widely investigated miRNA 
due to its pro-oncogenic activity demonstrated in differ- 
ent malignancies [122]. This miRNA is upregulated by 
the IL-6 downstream (described in previous section) and 
was found to be overexpressed in platinum-resistant EOC 
cell lines. In the same study, Lou et al. reported that the 
down-regulation of miR-21induced apoptosis and inhib- 
ited invasion and migration capabilities of EOC cell line, 
making this miRNA a possible candidate for future 
clinical translation [123].  
Non-coding RNAs represent one of the most exciting 
recent discovery in cancer biology and other different 
miRNAs, such as miR-29b or miR-221/222 are currently 
under investigation in different malignancies for their 
potential clinical application as anticancer agents [127- 
132].  
4. Conclusions 
Figure 1 and Table 2, describe all major pathways ment- 
ioned in our review. In the light of clinical trials results it 
is evident, to date, that only antiangiogenic agents (in 
particular bevacizumab) when associated to cytotoxic 
drugs are able to improve EOC patient outcome. Con- 
cerning other described pathway, probably pertuzumab  
About 63% of platinum-resistant EOC presented a 
dysfunctional TP53 pathway [124]. This event leads to 
the reduction of intracellular of the oncosuppressor miR- 
34a, thus improving cell capability to survive and metas- 
 
 
Figure 1. Major pathways involved in EOC pathogenesis and new potential targets. 
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Table 2. Phase II III studies targeting EOC. 
Study No. pts Patients Treatment RR SD Median PFS Median OS Most common grade ≥ 3 AE 
Cannistra  
et al. [59]  
No. 44 
Platinum-resistant 
EOC/PSC after 2 - 3 CT 
regimens 
Bevacizumab 15 mg/kg IV
q3 weeks; median no. of 
cycles, 5 
16% 61% 4.4 months 10.7 months 
GI perforation (11%),  
small intestinal obstruction (9%), 
Hy (9%), Fg (5%),  
abdominal pain (5%),  
or digestion (5%)  
and dyspnea (5%) 
Pujade-Lauriaine 
et al. [60]  
No. 361 
Platinum/resistent EOC 
after 1 - 2 CT regimens No 




evidence of rectosigmoid 
encolvement 
Bevacizumab 15 mg/kg IV
q3 weeks and/or CTa 
NR NR 6.7 months NR 
Netropenia  
(23% with P; 19% with T), 
PSN (35% grade ≥2 with P), 
HFS (28% grade ≥2 with PLD), 
Hy (12% with PDL) 
Burger 
et al. [102]  
No. 62 
Persistent/recurrent EOC or 
PPC after 1 - 2 CT regimens 
Bevacizumab 15 mg/kg IV
q3 weeks; median no. of 
cycles, 7 
21% 52% 4.7 months 16.9 months Hy (10%) and GI events (7%)
Garcia  
et al. [104] 
No. 70 
Recurrent EOC or PPC  
after 1 - 3 CT regimens 
Bevacizumab 10 mg/kg IV
q2 weeks and 
cyclophosphamide 50 mg daily 
orally; median no. of cycles, 5
24% 63% 6 months 16.9 months 
Lymphopenia (14 episodes), 
pain (13 episodes),  
Hy (11 episodes), Fg (6 episodes),
and GI obstruction (5 episodes).
Tillmanns  
et al. [106] 
No. 48 
Recurrent/platinum-resistant 
EOC/PPC after ≥1 prior 
regimen 
Bevacizumab 10 mg/kg IV
q2 weeks and nabpaclitaxel 
100 mg/m2; median no. of 
cycles, until progression 
46% 30.8 8.3 months 16.5 months 
Bowel obstruction (4%),  
nausea (4%), and nose bleed (4%)
Wagner 
et al. [73] 
No. 56 
Recurrent/platinum-resistant 




Tamoxifen 40 mg/day PO 
and gefitinib 500 mg/day PO 
until progression or 
unacceptable toxicity 
NR NR 58 days 253 days 
Diarrhea (NR%) and  
acne-like skin rash (NR%) 
Pautier 
et al. [74] 
No. 28 
Recurrent/platinum-resistant 
EOC/FTC/PPC; had  
previously received 
first-line platinum/taxane  
treatment only 
Gefitinib 500 mg/day PO, P 
(175 mg/m2 3 h  
infusion) and C (AUC 5) every
3 weeks, followed  
by gefitinib alone,  
median no. of received  
cycles 6 - 8. 
NR NR 6.1 months 16.9 months 
Neutropenia (59%), diarrhea 
(25%), leukopenia (22%), anemia 
(13%), and acne (13%). 
Weroha  
et al. [77] 
No. 18 
Recurrent/platinum-resistant 
EOC/PPC; had previously 
received first-line  
platinum/taxane  
treatment only 
Topotecan 3.2 mg/m 2 IV 
on day 1, 8 and 15 and 
lapatinib 1250 mg daily, 
continuously in 28 day 
cycles. PO 
NR NR 3.5 months 15.5 months 
Neutropenia (56%), 
Thrombocytopenia (28%),  
and diarrhea (22%). 
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et al. [80] 
No. 130 
Recurrent EOC/PPC; had 
previously received first-line 
treatment 
gemcitabine plus either 
pertuzumab or placebo 
NR NR 2.9 months 13.2 months 
Neutropenia (39 %), 
diarrhea (11%), back pain (9%) 
and Fg (22%) 
Bebakht  
et al. [81] 
No. 60 
Persistent/recurrent EOC/PPC 
who had  
received 1 - 3  
prior regimens 
Temsirolimus 25 mg 
weekly IV until  
progression or  
intolerable toxicity 
NR NR 3.1 months NR 
Metabolic (8 pts), 
GI (8 pts), pain (6 pts), 
and pulmonary (4 pts) 




EOC and symptomatic 
malignant ascites 
Aflibercept 4mg/kg every
2 weeks IV 
NR NR 59.5 days NR 
Hy and weight loss (1 pt) 
and intestinal perforation (1 pt)
Baumann  
et al. [114] 
No. 73 
recurrent platinum-resistant 
ovarian cancer who were 
pretreated with up to three 
chemotherapies 
sunitinib (arm 1: 50 mg daily
orally for 28 days followed by
14 days off drug; and arm 2: 







and abdominal symptoms, 
hematologic and hepatic labora-
tory abnormalities 
Biagi  
et al. [115] 
No. 30 
measurable disease and one or 
two prior chemotherapies, at 
least one platinum based. 
Platinum-sensitiveor resistant 
disease was allowed. 
50 mg daily, 4 of 6 weeks
37.5 mg daily continuously
NR NR NR 4.1 months 
Fg (3 pts), GI symptoms (4 pts),
HFS (3 pts) and Hp (1 pt). 
Abbreviations: RR, response rate; SD, stable disease; PFS, progression-free survival; OS, overall survival; NR, not reported; EOC, epithelial ovarian carcinoma; 
PSC, peritoneal serous carcinoma; PPC, primary peritoneal cancer; FTC, fallopian tube cancer; CT, chemotherapy; IV, intravenously; PO, oral dose; AUC, area 
under the concentration-time curve; AEs, adverse events; GI, gastrointestinal; Hp, hypertension; PSN, peripheral sensory neuropathy; HFS, hand-foot syndrome; 
Fg, fatigue. aCT options (investigator’s choice): Paclitaxel (P) 80 mg/m2 days 1, 8, 15, & 22 q4w; Topotecan (T) 4 mg/m2 days 1, 8, & 15 q4w (or 1.25 mg/m2, 
days 1 - 5 q3w); pegylated liposomal doxorubicin (PLD) 40 mg/m2 day 1 q4w. 
 
only may be a promising therapeutic option. 
It could be interest to achieve additional information 
on the role of miRNAs as predictive factors of outcome 
and/or as new therapeutic agents. Further studies are ea- 
gerly awaited to disclose the real potential of both mi- 
RNA and miRNA inhibitors as new drugs to translate 
into clinical practice. 
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